Literature DB >> 20154443

Subacute longitudinal myelitis associated with Behcet's disease.

Jiro Fukae1, Kazuyuki Noda, Kenji Fujishima, Toshiyuki Takahashi, Nobutaka Hattori, Yasuyuki Okuma.   

Abstract

In neuro-Behcet's disease (NBD), myelitis is a rare clinical form. We report the case of a woman with NBD presenting with unsteady gait and generalized spasticity. Spinal magnetic resonance imaging (MRI) showed multiple and confluent hyperintensities extending throughout the entire spinal cord on a T2-weighted image with some contrast enhancement. High-dose steroid therapy was so effective that the myelitis was markedly improved, as shown in the follow-up MRI. Longitudinal myelitis involving the entire spinal cord, as seen in our patient, has never been described before. This case suggests that NBD could be one of the important differential diagnoses of longitudinal myelitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154443     DOI: 10.2169/internalmedicine.49.2175

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

Review 1.  Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica.

Authors:  Corinna Trebst; Peter Raab; Elke Verena Voss; Paulus Rommer; Mazen Abu-Mugheisib; Uwe K Zettl; Martin Stangel
Journal:  Nat Rev Neurol       Date:  2011-11-01       Impact factor: 42.937

2.  Treatment of myelitis in Behçet's disease with rituximab.

Authors:  Maria Josè Messina; Mariaemma Rodegher; Roberta Scotti; Vittorio Martinelli
Journal:  BMJ Case Rep       Date:  2014-05-30

Review 3.  Clinical and imaging features of spinal cord type of neuro Behçet disease: A case report and systematic review.

Authors:  Hui-Miao Liu; Ci Dong; Yong-Zhi Zhang; Ya-Yun Tian; Hong-Xu Chen; Sai Zhang; Na Li; Ping Gu
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

Review 4.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.